Point-of-care Pharmacogenomic Testing to Optimize Isoniazid Dosing for Tuberculosis Prevention

Last updated: December 14, 2025
Sponsor: Stanford University
Overall Status: Completed

Phase

1

Condition

Lung Disease

Hiv

Treatment

Standard dose of isoniazid

Low-dose isoniazid

High-dose isoniazid

Clinical Study ID

NCT05413551
65808
1R21AI172182-01
  • Ages > 18
  • All Genders

Study Summary

This trial is designed to determine whether modifying the dose of isoniazid for individuals according to their n-acetyltransferase 2 (NAT2) genotype could increase the probability of achieving equivalence of area-under-the-curve.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Eligible for latent tuberculosis treatment by Brazil's national guidelines*

  • provides written informed consent to participate in the study

Exclusion

Exclusion Criteria:

  • Evidence of active tuberculosis or currently under evaluation for activetuberculosis

  • Receiving drugs that interact with Rifapentine (e.g. methadone, warfarin)

  • Known intolerance or hypersensitivity to isoniazid or rifapentine

  • Prior treatment for active or latent tuberculosis > 14 days

  • Close contact to isoniazid- or rifampicin-resistant tuberculosis (TB) case

  • Neutropenia (absolute neutrophil count <1000 cells/mm3)

  • Clinical diagnosis of active liver disease or alcohol dependence

  • alanine aminotransferase (ALT) or aspartate aminotransferase (AST) >3 times theupper limit of normal

Study Design

Total Participants: 73
Treatment Group(s): 3
Primary Treatment: Standard dose of isoniazid
Phase: 1
Study Start date:
March 23, 2023
Estimated Completion Date:
June 25, 2025

Connect with a study center

  • Federal University of Mato Grosso do Sul

    Campo Grande, Mato Grosso Do Sul
    Brazil

    Site Not Available

  • Federal University of Mato Grosso do Sul

    Campo Grande 3467747, Mato Grosso do Sul 3457415
    Brazil

    Site Not Available

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.